Ra Med Division Announces Product Launch of LockeT Device

Rhea-AI Summary

Ra Medical Systems, through its subsidiary Catheter Precision, has launched the LockeT product, initiating initial shipments to distributors this week. LockeT is designed to assist in the closure of percutaneous wound sites after catheter removal. It is positioned as a cost-effective alternative to existing closure devices like Perclose and Angioseal. The executive leadership expressed optimism about the product's market potential, highlighting its applicability to millions of percutaneous procedures across various medical domains such as cardiac electrophysiology and vascular surgeries. The feedback from healthcare professionals further emphasizes its user-friendly and low-cost design.

Positive

• Launch of LockeT product into the market, enhancing product portfolio.
• Addressing a significant market need with millions of applicable procedures.
• Positive feedback from medical professionals indicating high market demand.

Negative

• None.

Initial Shipments to Begin This Week

FORT MILL, SC / ACCESSWIRE / February 14, 2023 / Ra Medical Systems, Inc. (NYSE/American:RMED) announced today that its wholly owned subsidiary, Catheter Precision, Inc., has launched its LockeT product into the marketplace, with initial shipments to its distributors to begin immediately.

LockeT can be used in conjunction with the closure of a percutaneous wound site, where a catheter has been placed through the skin into a blood vessel and then removed at the end of a procedure. The physician will suture the site and the vessel, and LockeT is used to hold the sutures in place. Locket can either complement or be used as an alternative to closure devices. Those devices include Perclose, sold by Abbott, Vascade, sold by Cardiva, a unit of Haemonetics, and Angioseal, sold by Terumo.

David Jenkins, Executive Chairman of RMED, commented, "We are tremendously excited to bring our LockeT product to market. It addresses, in a very cost-effective manner, the marketplace for all percutaneous procedures, including cardiac electrophysiology, structural heart, and numerous vascular surgery procedures. In sum, it is a market with millions of procedures to which we believe LockeT applies. We are keenly interested in the early adaption and growth of this new product line."

Dhanunjaya (DJ) Lakkireddy, MD, Executive Director of the Kansas City Heart Rhythm Institute and Professor of Medicine at the University of Missouri, Columbia, also commented, "This is a user and patient friendly, low-cost, disruptive technology that will make vascular closure a lot simpler. We have highly anticipated the introduction of this product and it will have significant uptake very quickly. I believe vascular interventions could use such a tool all across the world and we will start putting it to use once it becomes available. The low cost and the simple design of this product is exactly what was needed."

About Ra Medical Systems

Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

CONTACTS:

At the Company

David Jenkins
973-691-2000
mhuck@catheterprecision.com

SOURCE: Ra Medical Systems, Inc.

View source version on accesswire.com:
https://www.accesswire.com/739197/Ra-Med-Division-Announces-Product-Launch-of-LockeT-Device

FAQ

What is the LockeT product launched by Ra Medical Systems?

The LockeT is a medical device designed to assist in closing percutaneous wound sites after catheter removal, offering a cost-effective alternative to existing closure devices.

When did Ra Medical Systems announce the launch of LockeT?

Ra Medical Systems announced the launch of LockeT on February 14, 2023.

How does LockeT compare to existing closure devices?

LockeT complements or serves as an alternative to devices like Perclose, Vascade, and Angioseal, potentially simplifying the vascular closure process.

What are the expectations for LockeT's market uptake?

Both company executives and healthcare professionals anticipate significant uptake for LockeT due to its user-friendly design and low cost.

Who commented on LockeT's market potential?

David Jenkins, Executive Chairman of RMED, and Dhanunjaya Lakkireddy, MD, have both commented positively on LockeT's market potential and expected uptake.